We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · May 24, 2021

Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Pembrolizumab Plus Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: An Open-Label, Multi-Arm, Non-Randomised, Multicentre, Phase 2 Trial
Lancet Oncol 2021 May 11;[EPub Ahead of Print], AG Sacco, R Chen, FP Worden, DJL Wong, D Adkins, P Swiecicki, W Chai-Ho, P Oppelt, D Ghosh, J Bykowski, A Molinolo, E Pittman, MV Estrada, K Gold, G Daniels, SM Lippman, A Natsuhara, K Messer, EEW Cohen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.